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2A B S TRA C T1
B ackgrou nd : Factor VIII (FVIII) and its carrier protein von Willebrand factor (VWF) are2
associated with risk of arterial and venous thrombosis and with hemorrhagic disorders. We3
aimed to identify and functionally test novel genetic associations regulating plasma FVIII and4
VWF.5
M ethods: We meta-analyzed genome-wide association results from 46,354 individuals6
of European, African, East Asian, and Hispanic ancestry. All studies performed linear regression7
analysis using an additive genetic model and associated approximately 35 million imputed8
variants with natural-log transformed phenotype levels. In vitro gene silencing in cultured9
endothelial cells was performed for candidate genes to provide additional evidence on10
association and function. Two-sample Mendelian randomization (MR) analyses were applied to11
test the causal role of FVIII and VWF plasma levels on the risk of arterial and venous thrombotic12
events.13
Resu lts: We identified 13 novel genome-wide significant (p≤2.5x10-8) associations; 7 with FVIII14
levels (FCHO2/TMEM171/TNPO1, HLA, SOX17/RP1, LINC00583/NFIB, RAB5C-KAT2A,15
RPL3/TAB1/SYNGR1, and ARSA) and 11 with VWF levels (PDHB/PXK/KCTD6, SLC39A8,16
FCHO2/TMEM171/TNPO1, HLA, GIMAP7/GIMAP4, OR13C5/NIPSNAP, DAB2IP, C2CD4B,17
RAB5C-KAT2A, TAB1/SYNGR1, and ARSA, beyond 10 previously reported associations with18
these phenotypes. Functional validation provided further evidence of association for all loci on19
VWF except ARSA and DAB2IP. MR suggested causal effects of plasma FVIII activity levels on20
venous thrombosis and coronary artery disease risk and plasma VWF levels on ischemic stroke21
risk.22
3C onclu sions:The meta-analysis identified 13 novel genetic loci regulating FVIII and VWF1
plasma levels, 10 of which we validated functionally. We provide some evidence for a causal2
role of these proteins in thrombotic events.3
4
CLINICAL PERSPECTIVE5
What is new?6
 Plasma coagulation factor VIII (FVIII) and von Willebrand factor (VWF) concentrations are7
associated with risk of cardiovascular disease, but the factors that control their levels are not8
fully understood.9
 Using a multi-ethnic meta-analysis of genome wide association studies, we identified 710
genome-wide significant novel associations for FVIII and 11 for VWF.11
What are the clinical implications?12
 We evaluated the effect of genetic variants with coronary artery disease, ischemic stroke, and13
venous thrombosis through Mendelian randomization analyses and found evidence of a14
causal effect of FVIII activity levels on venous thrombosis and coronary artery disease risk,15
and a causal effect of plasma VWF levels on stroke risk.16
 Our findings suggest that FVIII and VWF may be potential therapeutic targets to prevent17
thrombotic events.18
19
4IN TRO D UC TIO N1
Factor VIII (FVIII) and its carrier protein von Willebrand factor (VWF) regulate hemostasis and2
thrombosis, and higher plasma levels of these factors have been associated with risk of arterial3
and venous thrombosis, while lower levels are associated with hemorrhagic disorders1-4and with4
reduced risk of thrombotic events 5. Previously published genetic association studies have5
investigated the contribution of nucleotide variation to plasma levels of these factors using6
genome-wide and exome-wide markers6-8. These studies identified and replicated 8 genetic loci7
associated with plasma VWF levels (STXBP5, SCARA5, ABO, STAB2, STX2, VWF, TCN2 and8
CLEC4M), 5 of which were also associated with FVIII levels (STXBP5, SCARA5, ABO, STAB2,9
and VWF). These discoveries have broadened our understanding of the regulation of hemostasis10
through follow-up functional investigations9, 10.11
12
The causal effect of these factors on bleeding is well-established, since severe FVIII and VWF13
deficiencies lead to bleeding disorders hemophilia A and von Willebrand disease, respectively.14
While it is currently unclear whether FVIII and VWF levels causally influence the risk of15
thrombotic diseases, some genetic and observational evidence point towards an effect of these16
proteins on thrombotic disease. Genetic variants in F8 gene and in 3 VWF-associated genes17
(ABO, STXBP5 and VWF) are robustly associated with risk of venous thrombosis but no causal18
association has been established11-13.19
20
The aim of this investigation was to identify new genetic associations that influence plasma21
levels of FVIII and VWF by expanding the size and ancestral diversity of the discovery sample22
from previous genome-wide association studies (GWAS) and by improving coverage of the23
5genome through the use of 1000 Genomes imputed data and the inclusion of chromosome X1
variants14. For discoveries that reached genome-wide significance, we conducted first-pass2
functional characterization of the candidate loci both to provide additional evidence of3
association and to better understand the biology regulating plasma levels of these coagulation4
phenotypes. Last, by applying our genetic findings as instrument variables, we characterized the5
causal effect of plasma FVIII and VWF levels on clinical cardiovascular (CV) events using6
Mendelian randomization (MR) analyses.7
8
M E TH O D S9
Due to patient confidentiality agreements and to comply with the study participants consent, the10
original data and study materials cannot be made available to other researchers for purposes of11
reproducing the results or replicating the procedure. Analytic methods will be made available12
upon request, and summary statistics have been made publicly available through dbGaP.13
14
S tu dyD esign and P articipatingC ohorts15
This project was organized within the Cohorts of Heart and Aging Research in Genomic16
Epidemiology (CHARGE) Consortium Hemostasis Working Group15. We meta-analyzed17
phenotype-genotype associations of low-frequency and common (minor allele frequency [MAF]18
> 0.01) variants in 32,610 individuals from 9 studies with FVIII levels, and in 46,354 individuals19
from 18 studies with VWF levels. A total of 20 studies contributed to one or both of the20
analyses; these included participants of European (EUR), African (AFR), East Asian (ASI), and21
Hispanic (HIS) ancestry. Descriptions and ancestry composition of participating cohorts are22
found in Supplementary Table S1. All studies were approved by appropriate institutional review23
6committees and all participants gave written informed consent for themselves and their minor1
children for the use of their DNA.2
3
S tu dy-L evelM ethods4
Genotype Calling and Quality Control5
All participating cohorts performed genotyping using commercial genotyping platforms6
available from Illumina or Affymetrix. Each study performed genotyping quality control checks7
and imputed the approximately 35 million polymorphic autosomal and X-chromosome variants8
described in the 1000 Genomes population phase 1 version 3 for each participant using available9
imputation methods16. Variant calling and quality control procedures for each cohort are10
described in Supplementary Table S1.11
12
Association Analyses13
Plasma FVIII activity or VWF antigen levels were measured in all participants and reported in %14
or IU/ml*100 units. Participants with plasma FVIII or VWF levels (or activity levels) 3-15
standard-deviations above or below the population mean were removed, as were individuals on16
anticoagulation therapy. Natural-log transformed FVIII activity and VWF antigen levels (% or17
IU/ml*100 units) were analyzed separately within each study. Study-specific regression analyses18
using an additive model of inheritance were performed for imputed variant dosages and19
phenotype levels, adjusting for sex, age, study design variables, and population substructure20
using principal components. All analyses were stratified by ancestry and then meta-analyzed. X-21
chromosome variants were additionally stratified by sex, with dosage values for males coded as22
0/2.23
7M eta-A nalysis M ethods1
Quality Control2
Study-specific findings were uploaded centrally and a quality control (QC) pipeline of all3
individual studies prior to meta-analysis was conducted using the EasyQC software package17.4
Variants with beta or standard errors (SE) values > 5 or imputation values < 0.3 were excluded5
from the analysis. Estimated minor allele counts (eMAC) calculated for all SNPs were a function6
of allele frequency, total number of samples per cohort, and imputation quality; values <10 were7
excluded from analysis. Alleles were harmonized according to 1000 Genomes phase1 version38
reference panel and duplicated SNPs or SNPs that had inconsistencies with the reference were9
excluded.10
11
Meta, Trans-Ethnic, and Multi-Phenotype Discovery Analyses12
Meta-analyses were performed in METAL within each ancestry group using a fixed-effects13
inverse-variance weighted approach then combined in a trans-ethnic analysis using the same14
method18. The trans-ethnic analyses are presented as discovery results and we used the ancestry-15
specific analyses to inform and interpret these signals. An association was considered genome-16
wide statistically significant at p-value <2.5x10-8 to correct for the low-frequency variants that17
were not included in the initial generation of GWAS19 and only variants that passed QC in at18
least 3 cohorts were reported. Variants with MAF below 1% were filtered out after the meta-19
analyses. A genomic control coefficient was computed for each discovery cohort and was used to20
correct for cryptic relatedness. Finally, a locus was defined as +/- 1Mb from the SNP with the21
lowest p-value, and the SNP with the lowest p-value was selected to represent the locus. Multi-22
phenotype methods are described in Supplementary Methods.23
8Fu nctionalC haracterization of C andidate L ocithrou ghGene S ilencing1
In the absence of replication cohorts, we conducted first-pass functional characterization of the2
candidate loci to provide additional evidence of association. For each genome-wide significant3
locus, we selected candidate genes that could be responsible for the observed associations.4
Selection was based on proximity to the most associated SNPs in each region, information from5
public databases on putative effect of the SNPs in terms of regulation of expression and function6
of nearby genes, and hypothesis for a biological mechanism to regulate VWF/FVIII. This7
selection process identified 1 to 3 candidate genes for each associated locus. To screen for8
functionality, human umbilical vein endothelial cells (HUVEC; Life Line Cell Technology) were9
plated on collagen coated 96-well plates and transfected with siRNA (Silencer Select,10
ThermoFisher Scientific) directed against the candidate genes using the transfection reagent11
oligofectamine (ThermoFisher Scientific). Cells were cultured for 4 days after transfection, and12
media was then replaced with control media or media containing 10 µM of histamine for 3013
minutes, to stimulate an inflammatory response. The FVIII and VWF in the media was measured14
by an ELISA using antibodies from Fitzgerald Industries and had detection ranges of 0.003-0.2115
IU/ml for the FVIII assay and 0.5-120 ng/ul for the VWF assay. Every experiment was repeated16
4 times and results are expressed as the mean ± standard deviation (SD) of relative expression17
compared with a negative control (transfected with scramble siRNA).18
19
Follow-u pGenetic A nalyses20
Conditional Analyses21
To identify additional independent genetic signals at the associated loci, we used an approximate22
method implemented in GCTA for conditional and joint analysis using meta-analysis summary23
9statistics20. We used best-guess imputation for variants with imputation quality >0.3 in 8,4811
European-ancestry individuals from the Framingham Heart Study (FHS) as the reference panel.2
A description of the FHS is given in the Supplementary Methods. In order to prevent spurious3
conditional associations arising from a discrepancy between linkage disequilibrium in our4
GWAS and the reference panel, we also performed the conditional analysis on the results of the5
European-ancestry meta-analysis as a sensitivity analysis, since different genetic variants showed6
the strongest association in the trans-ethnic analysis compared with the European-only analysis.7
8
Mendelian Randomization9
For the sentinel variant in each locus in FVIII and VWF analyses, we conducted in silico lookups10
for the associations of each individual variant with 3 major CV events: coronary artery disease11
(CAD) in the CARDIOGRAMplusC4D Consortium21, 22, ischemic stroke (IS) in the12
MEGASTROKE analysis within the International Stroke Genetics Consortium23, and venous13
thromboembolism (VTE) in the International Network on Venous Thrombosis (INVENT)14
Consortium11. We conducted 2-sample Mendelian Randomization (MR) analyses to detect any15
potential causal effects of plasma FVIII and VWF levels on each CV outcome, separately. We16
used summary statistics to generate 1 causal estimate per significant locus as the ratio of the17
variant’s association with disease to the variant’s association with the exposure, and estimates18
were then meta-analyzed using an inverse-variance weighted approach as our primary MR19
estimate, known as the inverse-variance weighted (IVW) estimate24. Additional methods to avoid20
bias due to heterogeneity, and the final variants composing the instrumental variables are further21
described in Supplementary Methods and in Supplementary Tables S2, S3, and S4. Since FVIII22
plasma levels are largely determined by VWF plasma levels owing to VWF’s carrier role for23
10
FVIII in plasma, essentially all genetic predictors of plasma VWF levels are also predictors of1
FVIII plasma levels. The inverse, however is not true, and a small subset of variants predict2
FVIII plasma levels without predicting VWF levels. To investigate the independent causal role3
of FVIII plasma levels from that of VWF plasma levels on CVD events, we applied a4
multivariable MR (MVMR) approach where we adjusted for VWF variants effects in the5
estimate of causal association between FVIII and CVD outcomes25.6
7
RE S UL TS8
FV III,V W F,and M u lti-phenotype M eta-A nalyses9
Agnostic Discovery10
Data used for FVIII meta-analysis was available from 25,897 European (EA), 4,500 African11
(AA), 773 East or Indian Asian (EAA, IAA), and 1,440 Hispanic (HA) participants. Trans-ethnic12
meta-analysis for FVIII resulted 13,887,196 variants passing all filters, and identified 1,43113
variants that reached genome-wide statistical significance at 11 loci. Data used for VWF was14
available from 42,379 EA, 3,700 AA, and 275 HA participants. Meta-analysis for VWF resulted15
in 10,537,485 variants passing all filters, and identified 2,453 genome-wide significant variants16
at 17 loci (Figures 1A-B). European-specific meta-analysis identified one significant variant at17
one additional locus. Analysis using combined FVIII and VWF phenotypes (see Supplementary18
Methods) identified 2,828 variants reaching genome-wide significance at 2 additional loci, which19
were not identified in single-phenotype analyses.20
21
Table 1 shows the genetic discovery results for the FVIII, VWF, and combined FVIII-VWF22
phenotypes. Overall, 23 unique loci were identified. Among these, 13 were new associations not23
11
previously reported. Among the newly identified loci, 7 were associated with FVIII levels1
(FCHO2/TMEM171/TNPO1, HLA, SOX17/RP1, LINC00583/NFIB, RAB5C/KAT2A,2
RPL3/TAB1/SYNGR1/PDGB, and ARSA) and 11 were associated with VWF levels3
(PDHB/PXK/KCTD6, SLC39A8, FCHO2/TMEM171/TNPO1, HLA, GIMAP7/GIMAP4,4
OR13C5/NIPSNAP, DAB2IP, C2CD4B, RAB5C/KAT2A, RPL3/TAB1/SYNGR1/PDGB, and5
ARSA). Supplementary Figures S1a-n shows regional plots for the novel loci plotted for the 26
phenotypes. The lowest MAF for the index variant was 0.02 while the effect size per allele7
ranged from 0.015 to 0.032 (in log transformed units) for FVIII levels and from 0.014 to 0.0608
for VWF levels.9
10
Among the 23 genome-wide significant findings, 10 loci were previously reported to be11
associated with plasma levels of FVIII or VWF or both: STXBP5, SCARA5, ABO, ST3GAL4,12
STAB2, STX2, VWF, TCN2, CLEC4M, and TMLHE-F8 region.13
14
Conditional Analyses and Variant Characterization15
In follow-up analyses, we conditioned on sentinel variants to determine if secondary independent16
genome-wide significant signals were present. Results and additional independent variants are17
summarized in Table 2 along with findings from in silico investigations of the putative functional18
variant, and in Supplementary Tables S5 and S6. SCARA5, ABO, VWF and STAB2 were19
predicted to have more than one independent signal both for FVIII and VWF analyses (details in20
Supplementary Methods and in Supplementary Tables S5 and S6), some of which are in21
agreement with previous publications6. Among the independently associated variants within the22
ABO locus, SNPs rs10901252 and rs687621 perfectly discriminate B and O blood groups from23
12
A, and rs8176685 can reasonably capture information to tag A1/A2 (r2 0.59/D’ 0.99 with the tag1
SNP), confirming that ABO blood groups are essential determinants of VWF and FVIII plasma2
levels.3
4
Variance Explained5
Overall, the top variants for these loci (including the strongest independent associated variants in6
each locus that reached genome-wide significance after conditional analyses) explain 17% of the7
phenotypic variance for FVIII and 21.3% of the variance for VWF. ABO locus was by far the8
strongest determinant, alone explaining 13.6% and 16.2% of these variances, respectively.9
10
Fu nctionalA nalyses11
We silenced 21 genes across 12 loci to assess the in vitro impact on FVIII and VWF secretion12
(Figures 2a-b). These include the main candidate genes identified by proximity (Table 1). Our13
results suggest that 10 of the 12 candidate loci had one or more genes that changed VWF levels14
in media under basal and/or histamine-stimulated conditions. Specifically, silencing PDHB,15
SLC39A8, TMEM171, TNPO1, HLA-C, GIMAP7, NIPSNAP3A, NIPSNAP3B, C2CD4B, and16
SYNGR1 increased VWF release into media under basal conditions whereas ST3GAL4 silencing17
decreased VWF secretion. When cells were stimulated with histamine, silencing TMEM171,18
TNPO1, HLA-C, SNIPSNAP3A (but not SNIPSNAP3B), C2CD4B, KAT2A, and TAB1 increased19
VWF release in the media, and RAB5C decreased VWF secretion (Table 1; Figures 2a-b). For20
the experiments on the 5 genes that were only shown to be associated with FVIII levels21
(LINC00583, NFIB, SOX17, RP1 and TMLHE-F8), we could not find detectable levels of FVIII22
in media from treated HUVEC cells, and therefore the experiments were inconclusive.23
13
M endelian Randomization A nalyses and C ardiovascu larE vents1
Figure 3 show forest plots representing the results from MR analyses. We first analyzed FVIII2
and VWF individually using the IVW estimates that included the sentinel variant in each locus3
(after exclusion of variants with pleiotropic effects, see Supplementary Tables S2, S3, and S4).4
Both VWF and FVIII plasma levels showed a significant causal effect on CAD, IS and VTE risk.5
For CAD, the ORs associated with a per SD change in natural log-transformed FVIII and VWF6
were (OR(CI95) =1.15 (1.05, 1.27) and 1.14 (1.05, 1.23), respectively. For IS, the ORs(CI95) were7
1.28 (1.14, 1.43) and 1.19 (1.10, 1.29), respectively. For VTE, the ORs(CI95) were 2.75 (2.14,8
3.55) and 2.31 (1.89, 2.81), respectively. Sensitivity analyses using both MR-Egger regression9
and weighted median estimates support the IVW estimates and no significant pleiotropic effect10
was evident after exclusion of the pleiotropic loci (Figure 3, Supplementary Table S3,11
Supplementary Figures S2a-c).12
13
We then performed MVMR analyses of the FVIII phenotype to identify causal effects of FVIII14
activity levels independent of VWF levels. For VTE and CAD outcomes, adjustment of FVIII15
results by the effect of VWF, the ORs were modestly attenuated (20% and 16% respectively)16
compared with the unadjusted estimates and confidence intervals widened. For IS, however,17
adjustment of FVIII results by the effect of VWF resulted in an 86% attenuation of the OR(CI95)18
to 0.88 (0.51, 1.51). We could not demonstrate a causal association of VWF levels with VTE and19
CAD independent of FVIII levels.20
21
Of note, both the ABO and HLA loci were excluded from the instrumental variables for the MR22
analyses due to evidence of pleiotropic effects shown in the heterogeneity tests (Supplementary23
14
Table S3). When we estimated causal effects using ABO alone as an instrument, estimates of1
causal effects were essentially the same across phenotypes and outcomes: OR(CI95) 2.57 (2.47-2
2.67) for FVIII and VTE; OR(CI95) 2.28 (2.18-2.38) for VWF and VTE; OR(CI95) 1.10 (1.06-3
1.14) for FVIII and IS; OR(CI95) 1.09 (1.05-1.13) for VWF and IS; OR(CI95) 1.10 (1.06-1.14) for4
FVIII and CAD; and OR(CI95) 1.08 (1.04-1.12) for VWF and CAD.5
6
D IS C US S IO N7
In the present study, we meta-analyzed data from more than 36,000 individuals with FVIII levels8
and more than 46,000 with VWF and identified 13 novel loci, 7 of which associated with FVIII9
plasma levels and 11 associated with VWF levels. Overall, new discoveries yielded an additional10
6.2% and 8.1% proportion of variance explained for FVIII and VWF respectively from previous11
estimations8, and suggest that a great proportion of the genetic variance is explained by common12
variation. Further, we presented experimental evidence of biological function on VWF13
regulation for 14 of these genes from gene silencing in vitro: PDHB, SLC39A8, TMEM171,14
TNPO1, HLA-C, GIMAP7, NIPSNAP3A and B, ST3GAL4, C2CD4B, RAB5C, KAT2A, TAB1,15
SYNGR1. Last, we provide evidence in support of a causal role of FVIII levels on VTE and CAD16
events and of VWF levels on IS events.17
18
Characterization of the Novel Loci Regulating FVIII and VWF19
As expected for traits with strong genetic correlation, most of the newly associated loci20
regulate both FVIII and VWF levels in blood. Our results show that most of the highest-21
signal independent variants associated with these traits were located in introns or non-coding22
regions, although a substantial proportion were in strong LD (R2>0.8) with mutations23
15
causing missense or frameshift mutations in the nearby genes (Table 2 and Supplementary1
Table S7). We also explored eQTL associations using publically available data and we2
conducted pathway analyses for the novel loci. See Supplementary Methods and3
Supplementary Tables S8-S13 for this information.4
5
For most loci, several genes were identified within the associated region, and we selected 16
or more genes for further characterization using in vitro cell models. Based on our initial7
functional characterization, 1 or more plausible culprit genes regulating VWF secretion8
could be isolated at most loci. Interestingly, several candidate genes that showed a clear9
change in VWF levels upon silencing have been shown to participate in vesicle trafficking10
and exocytosis, as well as intracellular signaling and inflammatory response. The most11
relevant functional genes are described below.12
13
VWF Biogenesis, Vesicle Trafficking and Secretion14
ST3GAL4 is a Golgi transferase that catalyzes transfer of sialic acids in VWF glycan15
branches that are essential to its biogenesis, adhesive activity and clearance26. It also has a16
role in clearance of desialylated platelets with effects on platelet homeostasis. Genetic17
variants in ST3GAL4 locus have been associated with total cholesterol, LDL cholesterol,18
alkaline phosphatase, increased platelet aggregation, fibrinogen, CRP, and CAD (see further19
details and references in Supplementary Table S7). Our functional analyses showed a20
substantial reduction of VWF release upon ST3GAL4 silencing, which strengthens the21
evidence of this gene as a novel VWF regulator in basal conditions.22
23
16
SYNGR1 (Synaptogryn-1) encodes an integral membrane protein associated with presynaptic1
vesicles in neuronal cells. Several commonalities have been described between the exocytic2
machinery that drives vesicle trafficking and membrane fusion in endothelial cells and3
synaptic machinery found in neurons 27, 28, which suggest that SYNGR1 could have a role in4
vesicle trafficking and exocytosis of VWF from the Weibel-Palade bodies. Genetic variation5
in this locus has also been associated with IgG glycosylation, rheumatoid arthritis, and6
inflammatory bowel disease/Crohn’s disease, the last 2 consistent with an effect of7
deregulation of interleukin and inflammatory signaling pathways.8
9
NIPSNAP3A and NIPSNAP3B were selected as the main biologically plausible genes for10
locus on chromosome 9, and results from the functional study show evidence of significant11
upregulated levels of VWF upon silencing of either gene. Again, a reported role of these12
genes in vesicular trafficking29 suggest that these genes could be important in Weibel-Palade13
formation and exocytosis of VWF, both in basal conditions and under inflammatory stimuli.14
15
Among the 2 new loci found in the trans-ethnic multi-phenotype analysis, RAB5C is16
particularly interesting. It is a member of the Rab protein family, thought to ensure fidelity17
in the process of docking and fusion of vesicles with their correct acceptor compartment30,18
which may be relevant to the process of fusion of Weibel-Palate vesicles to release VWF in19
endothelial cells. RAB5C silencing caused a significant decrease of VWF release in media of20
endothelial cells upon stimulation with histamine.21
22
17
Our in vitro cell work showed a significantly increased VWF secretion upon PDHB1
silencing. PDHB codes for a subunit of the pyruvate dehydrogenase complex, which2
converts pyruvate to acetyl-CoA in the mitochondrion. We speculate that it is possible that3
the metabolism of endothelial cells regulates vesicle trafficking and exocytosis of VWF,4
meaning that the exocytosis process is dependent on the energetic status of the endothelial5
cell. Genetic variation in this locus has also been associated with total cholesterol, SLE, and6
RA.7
8
Intracellular Signaling and Inflammatory Response9
TAB1 silencing increased VWF released in media in our in vitro functional analyses,10
whereas no effect could be seen for PDGFB, a gene that has been implicated in CAD and11
VTE risk. TAB1 is a regulatory protein that acts as a mediator of several intracellular12
signaling pathways, especially those mediated by TGF-ß, WNT-1 and interleukin-1 which13
suggest it might have a role mediating VWF release upon certain cellular stimuli.14
15
Similarly, silencing C2CD4B gene in cultured endothelial cells resulted in strong16
upregulation of VWF release both in basal and under stimulus conditions. Allelic variants in17
this gene have also been associated with fasting glucose homeostasis and type 2 diabetes.18
Transcripts of this gene are predominantly found in the nuclear compartment of endothelial19
cells, and a possible role in regulation of transcription that might increase vascular20
permeability in acute inflammation has been suggested31. Similarly, TNPO1 codes for a21
nuclear receptor (Transportin-132) which mediates nuclear import of several proteins, which22
could also suggest a role in regulation of transcription under certain circumstances.23
18
1
DAB2IP is involved in several relevant cell-signaling pathways in response to inflammation,2
innate immune response, and cell growth inhibition, apoptosis, cell survival, angiogenesis,3
cell migration and maturation in endothelial cells, and genetic variation in this gene has been4
associated with abdominal aortic aneurysm and heart rate. Despite the strong genetic signal5
in our data, functional confirmation could not be achieved for DAB2IP in our secretion6
experiment so additional investigative work is needed.7
8
GIMAP7 showed a significant increase of VWF release upon silencing. GTPases of9
immunity-associated proteins (GIMAPs) are regulators of lymphocyte survival and10
homeostasis 33 although limited data have been published regarding the function of these11
proteins.12
13
Finally, although it did not reach genome-wide significance in the trans-ethnic meta-14
analysis, we found a single locus that close to SLC39A8 and that was genome-wide15
significant in our meta-analysis VWF associations in European-ancestry samples. This gene,16
which encodes a zinc transporter that functions in the cellular import of zinc at the onset of17
inflammation, has also been associated with blood pressure, high-density lipoprotein (HDL)18
cholesterol levels and BMI. Our functional work also suggested a strong effect on VWF19
levels in media from endothelial cells in vitro upon SLC39A8 silencing.20
21
Although further functional characterization of these genes is needed to fully characterize the22
role of all the investigated genes in VWF regulation, our results demonstrate that these studies23
19
are a valid tool to elucidate functional genes coming from genetic associations, and to shed light1
into the most relevant biological pathways implicated in the regulation of the phenotype under2
study.3
4
Mendelian Randomization and Clinical Implications5
Our results provide insights into the causal role of FVIII and VWF in 3 CV events, which are the6
leading causes of deaths globally.7
8
Biological and genetic evidence indicate that circulating FVIII levels are mainly determined by9
levels of VWF34. In the present study, we calculated the genetic correlation between VWF and10
FVIII based on the genome-wide association results from European-descent individuals (see11
Supplementary Methods) and found that the proportion of shared heritability of between these 212
phenotypes is 83.5%. This result is strengthened by the overlapping findings found in the13
individual GWAS, and suggests that, with some exceptions, the genetic pathways that regulate14
VWF levels indirectly regulate FVIII levels. Given the role of VWF regulating FVIII, we used 315
loci that were uniquely associated with FVIII independent of VWF and pursued conditional16
analyses that adjusted for the effect of VWF plasma levels to test the causal effect of FVIII on17
CV events. For IS, we found no evidence of a causal effect of FVIII independent of the VWF18
effect, which suggests that VWF biology may causally contribute to IS risk. For VTE and CAD,19
however, we found evidence supporting a causal effect of FVIII independent of the VWF effect.20
As there were no genetic loci that independently associated with VWF levels and not FVIII21
levels, we could not adjust the VWF analyses for FVIII. Nonetheless, given the similarities in the22
magnitude of the VWF-adjusted FVIII causal ORs with the VWF causal ORs for VTE and CAD,23
20
our data suggest that the VWF causal association for VTE and CAD may be driven primarily by1
the biologic effect of FVIII, although this hypothesis could not be tested.2
3
The results of the MR analyses suggest that both FVIII and VWF may be reasonable targets for4
the prevention or intervention of CAD and VTE while VWF may be a reasonable target for IS.5
These molecules are not currently pharmaceutical targets for the prevention of thrombotic6
events. In this paper, we report on 23 unique genetic loci associated with plasma levels of FVIII7
and/or VWF, of which 13 are newly reported associations. These discoveries offer new potential8
targets for the development of pharmaceutical agonistics or antagonists that may modulate9
thrombotic risk.10
11
Strengths and Limitations12
A major strength of the study was the relatively large sample size and the use of a denser13
imputation panel than was used in past discovery efforts. With this approach, we had hoped to14
identify uncommon associated variants but the MAF of the variants in the newly associated loci15
where relatively common, with just 1 variant having an MAF of less than 0.10. Our study design16
did not identify new associations marked by rare variation. Increasing the number of study17
participants to increase statistical power or improving the quality of the imputation from18
genotyping arrays may help to identify uncommon or rare variants associated with the outcomes.19
Some of the novel findings may be false positives, as we did not have access to independent20
populations to replicate our discoveries. Replication is required to validate genetic associations,21
especially for those close to the threshold for statistical significance. To offset this limitation, we22
conducted functional validation by silencing candidate genes and measuring VWF release; we23
21
view this functional work as a strength of the study. We were able to test only the regulation of1
VWF expression and not the regulation of VWF clearance by macrophages35. Nor were we able2
to test other mechanisms that regulates synthesis in megakaryocytes but not endothelial cells.3
Further, the need for a particular cellular stimulus that cannot be mimicked by histamine4
stimulation for the effect to be produced would be missed by our approach. Finally, it could be5
that the effect of some genetic associations can only be seen through overexpression rather than6
silencing of the gene. We attempted to also measure FVIII release but levels were too low so7
new models are required to validate the impact the candidate genes on FVIII levels; this is a8
limitation of our approach. All functional work was done in vitro, which carries limitations9
relative to in vivo investigations. The strong genetic co-regulation of both FVIII and VWF levels10
allowed us to conduct multi-phenotypes analyses and increase statistical power for discovery.11
Our MR approach using improved instrumental variants allows to establish for the first time a12
causal relationship between VWF and FVIII and several CV events. With only 3 loci associated13
with FVIII alone, the power of the VWF-adjusted MR analyses for FVIII and CV events was14
limited and we could not investigate the association of VWF on CV events independent of FVIII.15
There is a degree of overlap between our sample and the sample from consortia providing CV16
events GWAS data, which might create some bias in MR analyses36; this is a limitation of our17
work.18
19
C O N C L US IO N S20
We found 13 novel genetic loci with modest contributions to plasma levels of FVIII and/or21
VWF. Our discovery approach including first-pass functional validation has provided relevant22
information on the best candidate gene at the novel loci. Finally, MR analyses provided some23
22
evidence implicating FVIII plasma levels in the risk of CAD and VTE, and VWF plasma levels1
in the risk of IS. In summary, our work has identified novel loci regulating proteins essential for2
hemostasis and coagulation. These findings may provide genetic tools for therapeutic and3
preventive strategies and may be useful to identify new biologic pathways upon which to4
intervene to reduce the burden of arterial and venous outcomes.5
23
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Table 1:Main association results for FVIII and VWF trans-ethnic GWAS meta-analysis.1
Footnotes: “Freq” refers to the allele frequency of the effect allele. “B” = baseline; “S” =2
stimulated; “ns” = not significant; *p-value<0.05; **p-value<0.01; ***p-value<0.001.3
Beta and Frequency refer always to the Effect_allele, and they are expressed as natural-log4
transformed values from the original units (reported in % or IU/ml*100 units).5
†SLC39A8 was found in vWF meta-analysis of EA only (N=42,145).6
‡ Although not in LD with this variant, a low-frequency variant 665Kb upstream rs9271597 was7
found significantly associated to vWF levels (rs80082277; p=1x10-8) and we consider it within8
the HLA region; thus, we pursued this gene for further functional validation.9
§Olfactory receptor family was not considered for further functional validation for its low10
expression in the relevant tissues (mainly artery and whole blood).11
|| The ST3GAL4 locus was new at the time of analyses, although reported in a recent candidate12
gene study lacking replication (PMID: 27584569).13
# The highest associated SNP in this locus for FVIII is rs137631 (p=9.5x10-9), located close to14
RP L 3gene, 112Kb downstream TAB1/SYNGR1 locus and in low LD with rs575082315
(R2=0.14)16
¶ Chromosome X variant for VWF only available for EU samples (N=28.685).17
18
19
Table 2:Characteristics of all associated independent variants after conditional analyses.20
Footnotes: †LD with top variant in the region, calculated using FHS data. ‡Primary SNP was not21
well imputed in FHS and no other SNPs in the region achieved genome-wide significance in22
conditional analyses. “slct pJ” = joint p-value from GCTA "slct". “Original p-value” = p-value23
from discovery meta-analysis. The putative functional column indicates the best candidate24
variant in high linkage disequilibrium with the associated variant (R2>0.8) that has been25
identified in silico as the best candidate variant to have an impact on the adjacent gene/s. No26
functional work was performed in known genes, and these are symbolized by “-“ in the last27
column.28
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rs5595418 6 a g 0.36 35,513 0.011 2.2E-05 0.37 46,229 0.015 5.2E -09 PDHB, PXK, KCTD6 New PDHB (B =↑* * ; S =ns), PXK (B=ns; S=ns), KCTD6 (B=ns; S=ns)
rs68 55246 a g 0.93 35,513
-
0.003 0.672 0.92 46,068 -0.034
8 .68 E -
10 SLC39A8† New SLC39A8 (B=↑**) 
rs548 630 a c 0.49 36,286
-
0.016 2.1E -10 0.47 46,137 -0.018 1.2E -12
FCHO2, TMEM171,
TNPO1 New
FCHO (B=ns; S=ns),TMEM171 (B =↑* * * ; S =↑* ),TNPO1
(B =↑* * * ; S =↑* * )
rs9390460 t c 0.47 36,286
-
0.019 2.2E -15 0.46 46,212 -0.033 5.6E -42 STXBP5 Known -
rs927 1597 ‡ a t 0.41 28,203
-
0.015 1.4E -08 0.41 31,364 -0.012 2.1E-04 HLA region New HLA-C (B=↑**;s=↑***)
rs7 7 8 8 962 a g 0.62 33,773
-
0.010 2.3E-04 0.61 46,231 -0.014 7 .3E -09 GIMAP7, GIMAP4 New GIMAP7 (B =↑* * * ; S =ns), GIMAP4 (B=ns; S=ns)
rs427 6643 t c 0.66 36,286
-
0.023 1.3E -19 0.67 44,168 -0.029 8 .8 E -28 SCARA5 Known -
rs10102164 a g 0.19 36,286 0.019 2.4E -09 0.20 46,230 0.009 2.9E-03 SOX17, RP1 New Too little FVIII released by endothelial cells to be detected in vitro
rs647 9259 t c 0.73 28,535
-
0.021 1.1E-03 0.73 24,987 -0.056 1.5E -08 OR13C5, NIPSNAP§ New NIPSNAP3A (B =↑* ; S =↑* * ), NIPSNAP3B (B =↑* ; S =ns)
rs1098 5344 a g 0.25 36,286 0.011 7.5E-05 0.25 46,178 0.017 3.5E -09 DAB2IP New DAB2IP (B=ns; S=ns)
rs68 7 28 9 a g 0.36 36,286 0.145 1.9E -7 7 0 0.33 46,231 0.197
5.0E -
1443 ABO Known -
9:1393048 1:
ID d i 0.85 22,480
-
0.032 2.7 E -10 0.85 29,409 -0.003 4.4E-01 LINC00583, NFIB New Too little FVIII released by endothelial cells to be detected in vitro
rs35458 154 a g 0.03 33,871 0.048 3.1E-08 0.03 44,020 0.060 3.0E -12 ST3GAL4 Known || ST3GAL4 (B =↓* * ; S =ns)
rs498 1022 a g 0.69 36,286 0.025 3.0E -20 0.69 46,232 0.035 6.6E -41 STAB2 Known -
rs47 597 8 7 a c 0.40 36,286 0.011 1.1E-05 0.37 46,180 0.023 7 .7 E -20 STX2 Known -
rs2238 109 a t 0.39 36,286 0.026 3.5E -24 0.38 46,232 0.050 1.8 E -8 9 VWF Known -
rs49048 20 a g 0.49 36,286 0.014 1.8 E -08 0.47 46,232 0.022 6.0E -19 TCN2 Known -
rs6494314 t c 0.18 36,286
-
0.007 2.4E-02 0.17 46,232 -0.018 1.1E -08 C2CD4B New C2CD4B (B =↑* ; S =↑* * )
rs18 69365 Significant in combined multiphenotype analysis <5.0E -8 RAB5C, KAT2A New RAB5C (B=ns; S=↓*), KAT2A  (B=ns; S=↑**)
rs227 7 998 a g 0.30 33,097
-
0.010 4.4E-04 0.30 45,566 -0.022 6.5E -16 CLEC4M Known -
rs57 508 23# t c 0.70 36,286
-
0.013 1.5E-06 0.72 46,230 -0.020 6.0E -14
RPL3, TAB1, SYNGR1,
PDGB New
TAB1 (B =ns;S =↑* * ), SYNGR1 (B =↑* ; S =ns), PDGFB (B=ns;
S=ns)
rs96168 97 Significant in combined multiphenotype analysis <5.0E -8 ARSA New ARSA (B=ns; S=ns)
rs150926226
¶ c g 0.62 20,537 0.017 3.3E -09 0.65 28,685 -0.005 7.0E-02 TMLHE, F8 Known Too little FVIII released by endothelial cells to be detected in vitro
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5:7 2406659 rs548 630
TN P O 1;FC H O 2;
TM E M 17 1 9.5kb 5'TM E M 17 1 5.14E -10 3.96E -10 2.10E -10 2.06E -10 5:7 2406659 Topvariant Topvariant
6:147701217 rs9390461 STXBP5 intronic rs1039084, missense 2.74E-13 4.06E-13 1.73E-14 - 6:147703299 0.98 1.00
6:147 7 03299 rs9399599 S TX B P 5 intronic rs103908 4,missense 3.7 3E -13 - 1.41E -15 4.7 0E -16 6:147 7 03299 Topvariant Topvariant
8:27778148 rs55829013 SCARA5 intronic 3.39E-10 8.54E-10 5.81E-10 - 8:27805815 0.51 0.77
8:27823832 rs11780263 SCARA5 intronic 3.41E-17 6.96E-17 1.39E-19 - 8:27805815 0.10 0.98
8 :27 8 058 15 rs7 8 1657 9 S C A RA 5 intronic S iP hyconserved 5.32E -16 - 6.52E -21 4.07 E -21 8 :27 8 058 15 Topvariant Topvariant
8 :55421614 rs10102164 S O X 17 ;RP 1 intergenic 1.66E -07 - 2.38 E -09 2.44E -09 8 :55421614 Topvariant Topvariant
9:1393048 1:ID rs35468 07 4 L IN C 0058 3 intronic 1.7 4E -10 1.24E -10 2.66E -10 3.10E -10 9:1393048 1:ID Topvariant Topvariant
9:136116662 rs11793768 ABO 14 Kb 3' ABO 3.74E-13 1.29E-62 2.16E-13 - 9:136132908:ID 0.08 0.72
9:136137065 rs687621 ABO intronic 1.18E-647 p<1E-320 6.85E-778 - 9:136132908:ID 0.89 0.98
9:135976698 rs35108384 ABO intronic 4.58E-12 - 2.24E-12 6.53E-12 9:136132908:ID 0.00 0.14
9:136114000 rs78490142 ABO 17 kb 3' ABO 1.12E-03 - 6.53E-05 1.48E-13 9:136132908:ID 0.01 1.00
9:136132908 :ID rs8 17 67 19 A B O intronic S iP hyconserved 1.62E -307 - 3.52E -403
p<1E -
320 9:136132908 :ID Topvariant Topvariant
9:136178821 rs574237 ABO intergenic 2.89E-29 - 6.94E-38 5.38E-26 9:136132908:ID 0.01 0.18
9:136181539 rs551924 ABO intergenic 2.81E-48 - 9.21E-75 2.20E-63 9:136132908:ID 0.00 0.14
9:136207218 rs607900 ABO intergenic
rs116779216,
missense SURF1 6.86E-03 - 3.21E-15 1.85E-13 9:136132908:ID 0.00 0.19
9:136255149 rs62575992 ABO intergenic 3.46E-42 - 8.45E-45 1.83E-26 9:136132908:ID 0.02 0.80
9:136344853 rs3124758 ABO intergenic 2.71E-21 - 1.74E-18 5.88E-15 9:136132908:ID 0.00 0.14
12:6062894 rs57040304 VWF intronic
rs7962217, missense,
SiPhy cons 1.51E-15 1.22E-14 7.71E-12 - 12:6160614 0.00 0.09
12:6160614 rs7 135039 V W F intronic rs10638 56,missense 3.00E -19 7 .02E -18 2.32E -24 7 .21E -20 12:6160614 Topvariant Topvariant
12:6070845 rs12423482 VWF intronic
rs7962217, missense,
SiPhy cons 2.49E-15 - 2.92E-18 1.57E-17 12:6160614 0.00 0.15
12:6160146 rs11064010 VWF intronic 8.36E-07 - 2.41E-11 2.51E-09 12:6160614 0.01 0.33
12:104000319 rs1070073 STAB2 intronic 1.07E-13 5.04E-13 2.25E-14 - 12:104149874 0.00 0.16
12:104147207 rs3751198 STAB2 intronic 2.16E-17 5.91E-17 5.88E-18 - 12:104149874 0.70 0.98
12:104000470 rs2723889 STAB2 intronic 1.08E-13 - 2.14E-14 1.21E-14 12:104149874 0.00 0.16
12:1041498 7 4 rs498 1022 S TA B 2 intronic 1.16E -17 - 2.95E -20 4.47 E -21 12:1041498 7 4 Topvariant Topvariant
14:92268531 rs10498631 TC2N intronic 6.69E-09 8.63E-09 2.30E-08 - 14:92302972 0.54 0.82
14:9230297 2 rs58 2048 30 TC 2N intronic 2.57 E -08 - 6.28 E -09 7 .03E -09 14:9230297 2 Topvariant Topvariant
22:397 17 7 06 rs137 631 RP L 3 1.3Kb5´ of RP L 3 2.35E -07 - 9.48 E -09 1.34E -08 22:397 17 7 06 Topvariant Topvariant
3X :1547 21357 rs150926226 TM L H E ,F8
‡
3.25E -09
‡
X :1547 21357 - -
V W F(n=42,256 E UR;n=46,232 TRA N S )
3:58383174 rs55692656 PXK; KCTD6; PDHB intronic PXK
rs56384862, missense
PXK; rs34579268
missense PXK;
rs200687616
frameshift PDHB
6.48E-09 1.01E-08 3.33E-08 - 3:58436476 0.94 1.00
3:58 43647 6 rs5595418 6 P X K;KC TD 6;P D H B 17 kb 3´ of P X K
rs5638 48 62,missense
P X K;rs3457 9268
missense P X K;
rs20068 7 616
frameshiftP D H B
8 .7 2E -09 - 5.20E -09 8 .06E -09 3:58 43647 6 Topvariant Topvariant
5:72403453 rs7733340
TNPO1; FCHO2;
TMEM171 intergenic 5.80E-13 1.52E-12 3.40E-12 - 5:72406659 0.93 0.99
5:7 2406659 rs548 630
TN P O 1;FC H O 2;
TM E M 17 1 9.5kb 5'TM E M 17 1 1.33E -12 - 1.22E -12 6.19E -13 5:7 2406659 Topvariant Topvariant
6:31192766 rs9263993 HLA region intergenic 8.54E-09 3.50E-09 1.69E-07 - 6:31925848 0.00 0.63
6:31941629 rs116420479 HLA region intronic STK19 3.10E-08 1.49E-08 1.02E-08 - 6:31925848 0.94 0.98
6:31158633 rs9263861 HLA region intergenic 3.08E-08 - 3.25E-08 8.64E-09 6:31925848 0.00 1.00
6:31906828 rs78593564 HLA region intronic C2 3.15E-08 - 1.03E-08 2.76E-09 6:31925848 1.00 1.00
6:147 694334 rs9390460 S TX B P 5 intronic rs103908 4,missense 6.32E -38 1.67 E -38 5.58 E -42 1.27 E -42 6:147 694334 Topvariant Topvariant
7:150296496 rs13230842 GIMAP7; GIMAP4 intergenic 2.06E-08 1.96E-08 2.95E-08 - 7:150227227 0.18 0.97
7 :150227 227 rs7 7 8 8 962 GIM A P 7 ;GIM A P 4
9.1Kb3´ of
GIM A P 7 6.29E -08 - 7 .30E -09 1.36E -08 7 :150227 227 Topvariant Topvariant
8 :27 8 03599 rs427 6643 S C A RA 5 intronic 5.7 7 E -27 1.19E -29 8 .7 7 E -28 7 .69E -31 8 :27 8 03599 Topvariant Topvariant
8:27815481 rs62496810 SCARA5 intronic 3.74E-08 4.38E-11 4.98E-08 6.04E-11 8:27803599 0.02 1
9:124416940 rs1098 5344 D A B 2IP intronic 4.11E -09 3.7 6E -09 3.47 E -09 - 9:124416940 Topvariant Topvariant
9:124421965 rs4837886 DAB2IP intronic 3.84E-09 - 4.43E-09 3.94E-09 9:124416940 0.79 0.97
9:135919501 rs138796740 ABO intergenic 2.61E-08 7.06E-11 3.59E-08 - 9:136132908:ID 0.00 0.15
9:136128546 rs7857390 ABO 2.5Kb 3' of ABO p<1E-320 7.81E-294 2.15E-393 - 9:136132908:ID 0.36 1
9:136145414:ID rs202001822 ABO intronic 5.90E-78 1.46E-39 2.26E-80 - 9:136132908:ID 0.10 1
9:136147553 rs660340 ABO intronic p<1E-320 p<1E-320 1.11E-492 - 9:136132908:ID 0.33 0.87
9:136177394 rs656105 ABO intergenic 1.20E-66 2.62E-129 4.23E-73 - 9:136132908:ID 0.02 0.19
9:136128000 rs10901252 ABO 3.1 Kb 3' of ABO
rs8176747, missense;
rs8176746, missense;
rs8176743 missense
1.78E-291 - 2.61E-351 p<1E-320 9:136132908:ID 0.16 0.99
9:136130677 rs62641786 ABO 3'UTR 2.79E-96 - 2.59E-106 8.85E-30 9:136132908:ID 0.03 0.91
9:136138765:ID rs8176685 ABO intronic p<1E-320 - 5.95E-507 p<1E-320 9:136132908:ID 0.31 1
9:136316367 rs28680325 ABO intronic ADAMTS13 1.04E-09 - 2.88E-10 1.12E-09 9:136132908:ID 0.01 0.25
11:1262968 25 rs35458 154 S T3GA L 4 intronic 6.35E -12 8 .31E -12 2.96E -12 2.42E -12 11:1262968 25 Topvariant Topvariant
12:6157394 rs2283335 VWF intronic rs1063856, missense 6.48E-83 5.55E-79 2.08E-89 - 12:6153967 1 1
12:6160146 rs11064010 VWF intronic 1.60E-27 8.75E-22 7.90E-27 2.40E-21 12:6153967 0.01 0.30
412:6225931 rs112814955 VWF intronic 1.43E-42 3.14E-49 9.02E-43 4.00E-50 12:6153967 0.01 0.34
12:6153967 rs2238 109 V W F intronic rs10638 56,missense 1.37 E -8 2 - 1.7 7 E -8 9 3.41E -8 7 12:6153967 Topvariant Topvariant
12:104000319 rs1070073 STAB2 intronic 2.28E-36 8.23E-31 2.03E-36 6.72E-32 12:104149874 0.00 0.16
12:104007418 rs11111679 STAB2 intronic 2.31E-14 4.79E-10 1.22E-14 1.60E-10 12:104149874 0.00 0.02
12:104127353 rs73192004 STAB2 intronic rs17034433, missense 2.29E-08 2.33E-08 5.09E-09 6.57E-09 12:104149874 0.01 0.53
12:1041498 7 4 rs498 1022 S TA B 2 intronic 5.44E -37 4.69E -41 6.57 E -41 8 .65E -45 12:1041498 7 4 Topvariant Topvariant
12:131287011 rs6486599 STX2 intronic rs17564, missense 4.23E-18 1.92E-18 1.14E-18 - 12:131290180 1.00 1
12:13129018 0 rs47 597 8 7 S TX 2 intronic rs17 564,missense 4.45E -18 - 7 .7 3E -20 3.8 4E -20 12:13129018 0 Topvariant Topvariant
14:92290744 rs10498632 TCN2 intronic 2.58E-18 4.74E-18 5.00E-18 - 14:92318935 0.53 0.99
14:92318 935 rs49048 20 TC N 2 intronic 8 .30E -18 - 6.04E -19 2.40E -19 14:92318 935 Topvariant Topvariant
15:62455019 rs6494314 C 2C D 4B 7 00bp3´ of gene rs8 0407 12,missense 9.63E -08 - 1.14E -08 1.30E -08 15:62455019 Topvariant Topvariant
19:7 8 31628 rs227 7 998 C L E C 4M missense rs227 7 998 ,missense 2.02E -15 7 .30E -16 6.47 E -16 1.7 4E -15 19:7 8 31628 Topvariant Topvariant
22:39790191 rs2413590 PFGFB; SYNGR1; TAB1 5.6Kb of TAB1 3.96E-12 4.44E-12 2.02E-12 - 22:39829973 0.75 0.94
22:398 2997 3 rs57 508 23 P FGFB ;S Y N GR1;TA B 1 intronic TA B 1 2.98 E -11 - 5.95E -14 7 .58 E -14 22:398 2997 3 Topvariant Topvariant
1Figu re L egends
Figu re 1A : Manhattan plot for the trans-ethnic analyses FVIII (named by closest gene)
2Figu re 1B : Manhattan plot for the trans-ethnic analyses VWF (named by closest gene).
3Figu re 2A .Silencing candidate genes changes basal release of VWF.
HUVEC cells were transfected with siRNA against selected genes for 4 days, the media was
changed, cells were cultured for 30 min, and VWF was measured in the supernatant via ELISA.
n = 4 ± S.D. *p<0.05, **p<0.01, ***p<0.001. All results are relative to VWF release after
transfection with a scrambled control siRNA, which is set as reference (100%).
Figu re 2B .Silencing candidate genes changes stimulated release of VWF.
HUVEC cells were transfected with siRNA against selected genes for 4 days, the media was
changed, cells were stimulated with histamine 10 µM for 30 min, and VWF was measured in the
supernatant by an ELISA. n = 4 ± S.D. *p<0.05, **p<0.01, ***p<0.001. All results are relative
to VWF release after transfection with a scrambled control siRNA, which is set as reference
(100%).
4
5Figu re 3
Mendelian Randomization results. Results show OR (95% confidential interval) per every higher
standard deviation change in FVIII and VWF. CAD (Coronary Artery Disease), IVW(inverse-
variance weighted method), IVW.adjusted (IVW FVIII adjusted for the effects of VWF).
a) FVIII
6b) VWF
7S u pplementarymaterial
Supplementary Table S1: Descriptions of participating cohorts and resources
Supplementary Table S2: Final SNPs composing instrumental variables
Supplementary Table S3: MR results for the instrumental variables individually
Supplementary Table S4: global results for the Egger Regression to evaluate heterogeneity,
before and after exclusions
Supplementary Table S5: Results from conditional analyses from European-only data
Supplementary Table S6: Results from conditional analyses from transethnic data
Supplementary Table S7: Haploreg/SNIPA/GWAS catalogue for all transethnic top-SNPs
Supplementary Table S8: eQTL in other tissues
Supplementary Table S9: eQTL in whole blood
Supplementary Table S10: Factor VIII enrichment networks
Supplementary Table S11: Factor VIII prioritized genes in networks
Supplementary Table S12: von Willebrand factor enrichment networks
Supplementary Table S13: von Willebrand factor genes in networks
Supplementary Figures S1a-n: Regional plots for the novel associations
Supplementary Figures S2a-c: Scatter plots for the genetic associations between FVIII and
cardiovascular events
Supplementary Figure S3: Figure shows the hypothesized effect of the genes found in the present
study in relation to the possible regulatory points in VWF synthesis and secretion from
endothelial cells. The specific regulatory point suggestion is based on previous literature
evidence. Of note, VWF clearance or regulation in platelets were not studied in our in vitro first-
pass analyses.
